Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 642

1.

Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.

Toprover M, Crittenden DB, Modjinou DV, Oh C, Krasnokutsky S, Fisher MC, Keenan RT, Pillinger MH.

Bull Hosp Jt Dis (2013). 2019 Mar;77(2):87-91.

PMID:
31140959
2.
3.

Reduction of Leukocyte Microvascular Adherence and Preservation of Blood-Brain Barrier Function by Superoxide-Lowering Therapies in a Piglet Model of Neonatal Asphyxia.

Ruden JB, Quick KL, Gonzales ER, Shah AR, Park TS, Kennedy N, Dugan LL, Gidday JM.

Front Neurol. 2019 May 1;10:447. doi: 10.3389/fneur.2019.00447. eCollection 2019.

4.

Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.

Brackman DJ, Yee SW, Enogieru OJ, Shaffer C, Ranatunga D, Denny JC, Wei WQ, Kamatani Y, Kubo M, Roden DM, Jorgenson E, Giacomini KM.

Clin Pharmacol Ther. 2019 Mar 28. doi: 10.1002/cpt.1439. [Epub ahead of print]

PMID:
30924126
6.

Uric acid analogue as a possible xenobiotic marker of uric acid transporter Urat1 in rats.

Arakawa H, Amezawa N, Katsuyama T, Nakanishi T, Tamai I.

Drug Metab Pharmacokinet. 2019 Apr;34(2):155-158. doi: 10.1016/j.dmpk.2018.12.003. Epub 2018 Dec 27.

PMID:
30826184
7.

A letter of reply to the commentary by Dr. Stamp et al.

Ichida K.

Drug Metab Pharmacokinet. 2019 Feb;34(1):111-112. doi: 10.1016/j.dmpk.2018.12.001. Epub 2018 Dec 15. No abstract available.

PMID:
30709683
8.

How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.

Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N.

Arthritis Res Ther. 2018 Nov 16;20(1):255. doi: 10.1186/s13075-018-1755-0.

9.

Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.

Lindsay A, McCourt PM, Karachunski P, Lowe DA, Ervasti JM.

Free Radic Biol Med. 2018 Dec;129:364-371. doi: 10.1016/j.freeradbiomed.2018.10.404. Epub 2018 Oct 10.

PMID:
30312761
10.

ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.

Stamp LK, Wallace M, Roberts RL, Frampton C, Miner JN, Merriman TR, Dalbeth N.

Drug Metab Pharmacokinet. 2018 Dec;33(6):241-242. doi: 10.1016/j.dmpk.2018.09.002. Epub 2018 Sep 18. No abstract available.

PMID:
30274827
11.

Measurement of nitrate and nitrite in biopsy-sized muscle samples using HPLC.

Troutman AD, Gallardo EJ, Brown MB, Coggan AR.

J Appl Physiol (1985). 2018 Nov 1;125(5):1475-1481. doi: 10.1152/japplphysiol.00625.2018. Epub 2018 Aug 16.

PMID:
30113272
12.

Mechanisms leading to T-cell activation in drug hypersensitivity.

Meng X, Yerly D, Naisbitt DJ.

Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):317-324. doi: 10.1097/ACI.0000000000000458. Review.

PMID:
29905574
13.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.

J Clin Pharmacol. 2018 Sep;58(9):1214-1222. doi: 10.1002/jcph.1119. Epub 2018 May 7.

14.

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.

Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hall J, Liu S, Shen Z, Gillen M, Hernandez-Illas M.

RMD Open. 2018 Feb 8;4(1):e000584. doi: 10.1136/rmdopen-2017-000584. eCollection 2018.

15.

Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.

Aksenov S, Peck CC, Eriksson UG, Stanski DR.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13614.

16.

Insight on specificity of uracil permeases of the NAT/NCS2 family from analysis of the transporter encoded in the pyrimidine utilization operon of Escherichia coli.

Botou M, Lazou P, Papakostas K, Lambrinidis G, Evangelidis T, Mikros E, Frillingos S.

Mol Microbiol. 2018 Apr;108(2):204-219. doi: 10.1111/mmi.13931. Epub 2018 Mar 6.

PMID:
29437264
17.

Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity.

Usui T, Faulkner L, Farrell J, French NS, Alfirevic A, Pirmohamed M, Park BK, Naisbitt DJ.

Chem Res Toxicol. 2018 Mar 19;31(3):165-167. doi: 10.1021/acs.chemrestox.8b00030. Epub 2018 Feb 14.

PMID:
29436218
18.

Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, Morsch ALB, da Silva Stein F, Campos GGD.

BMC Cardiovasc Disord. 2018 Feb 7;18(1):24. doi: 10.1186/s12872-018-0757-9. Review.

19.

Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography-tandem mass spectrometry method in human plasma.

Rathod DM, Patel KR, Mistri HN, Jangid AG, Shrivastav PS, Sanyal M.

J Pharm Anal. 2017 Feb;7(1):56-62. doi: 10.1016/j.jpha.2016.05.005. Epub 2016 May 26.

20.

Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.

Nakamura M, Fujita K, Toyoda Y, Takada T, Hasegawa H, Ichida K.

Drug Metab Pharmacokinet. 2018 Feb;33(1):77-81. doi: 10.1016/j.dmpk.2017.11.002. Epub 2017 Nov 22.

PMID:
29342419

Supplemental Content

Loading ...
Support Center